<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734732</url>
  </required_header>
  <id_info>
    <org_study_id>2014--‐002999--‐83</org_study_id>
    <nct_id>NCT02734732</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole</brief_title>
  <official_title>Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine if a single dose of Ciprofloxacin and Trimethoprim/Sulfamethoxazole
      are equivalent for prophylaxis immediately prior to prostate biopsy, when a patient has a
      suspected prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The number of prostate biopsies are estimated to approximately 1.000.000 each
      year I Europe1. The infection rates after transrectal prostate biopsy are increasing
      annually2. The most common antibiotic used for prophylaxis is Ciprofloxacin, however,
      Trimethoprim/Sulfamethoxazole is also a feasible alternative3.

      Aim: To evaluate the best antibiotic prophylaxis prior to trans rectal prostate biopsy in low
      risk patients.

      Outcome: Hospitalization for infection within 14 days from biopsy.

      Method: By randomization of all eligible patients with low risk of infectious complications.
      Patient and treating physician is blinded to treatment allocation. By using the nationwide
      and full coverage national patient register (NPR), mandatory for inpatient care4. All
      patients can be identified by the Swedish personal identification number5. Both patients
      related baseline characteristics is gathered through register linkages. To validate the
      outcome variables, for all patients admitted to hospital within 14 days will be subject for
      chart review. Comparing all patients from the participating units, having a code specific to
      trans rectal biopsy, and comparing to the excluded patients as well as included patients,
      will make a separate exclusion analysis.

      The standard operating procedure for randomization is that patients will fill a form and
      informed consent of participation prior to the planned biopsy. If no exclusion criteria are
      filled and informed consent obtained, patient will be randomized through a web based
      randomization program, where only date of biopsy, earlier prostate biopsy, number of
      biopsies, PSA and prostate size is collected. Other baseline variables will be obtained by
      cross linkage to the NPR and the National Prostate Cancer Registry. A randomization number is
      given to all patients at this stage and a key code is established at each participating unit
      containing every patient randomization number and subsequent personal identification number.

      After complete requirement, data will be collected at Västernorrlands Läns Landsting and
      analyzed according to protocol.

      Analysis will be made by logistic regression and point estimates with Single sided 97.5%
      Confidence Interval. Sample size is calculated to require 2800 patients assuming a 0.5%
      frequency of infections, able to detect a difference of 0.75% in absolute proportion of
      infections.

      Missing data on outcome variable, received treatment or date of biopsy will be excluded from
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Admitted to hospital due to infection</measure>
    <time_frame>14 days</time_frame>
    <description>Admission to hospital within 14 days from biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Filled antibiotic prescription</measure>
    <time_frame>Within 30 days</time_frame>
    <description>A filled prescription within 14 days from biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive urinary or blood culture</measure>
    <time_frame>Within 30 days</time_frame>
    <description>A positive urinary or blood culture obtained within 14 days from biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any hospital admission</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Admission to hospital within 14 days from biopsy, regardless of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mortality</measure>
    <time_frame>Within 90 days</time_frame>
    <description>Overall mortality within 90 days from biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological characteristics</measure>
    <time_frame>Within 30 days</time_frame>
    <description>Resistance patterns and species of bacteria in blood or urinary cultures within 14 days from biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation time</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Number of days admitted to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total doses of antibiotics filled</measure>
    <time_frame>Within 30 days</time_frame>
    <description>The total amount of antibiotics filled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for infection</measure>
    <time_frame>Within 30 days</time_frame>
    <description>Other risk factors for infection apart from exclusion criteria, in baseline variables</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2800</enrollment>
  <condition>Prostate Infection</condition>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T. Ciprofloxacin 750mg, single dose immediately prior to prostate biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trimethoprim/Sulfamethoxazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trimethoprim/Sulfamethoxazole 160mg/800mg immediately prior to prostate biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim/Sulfamethoxazole</intervention_name>
    <arm_group_label>Trimethoprim/Sulfamethoxazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for trans rectal prostate biopsy (Physicians discretion)

          -  Informed consent

        Exclusion Criteria:

          -  Diabetes Mellitus

          -  Indwelling urinary catheter

          -  Prior urinary infection (last 6 months)

          -  Dipstick positive (Nitrites test)

          -  Allergy to Ciprofloxacin or Trimethoprim/Sulfamethoxazole

          -  Severe liver disease

          -  Concomittant use of Tizanidine

          -  Immunosuppression
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Styrke, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johan Styrke, M.D, Ph.D</last_name>
    <phone>0046-60181000</phone>
    <email>johan.styrke@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karl-Johan Lundström, M.D</last_name>
    <phone>0046-704941642</phone>
    <email>karl-johan.lundstrom@jll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Östersunds hospital</name>
      <address>
        <city>Östersund</city>
        <state>Jämtland</state>
        <zip>83130</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl-Johan Lundström</last_name>
      <email>karl_johan@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sundsvalls hospital</name>
      <address>
        <city>Sundsvall</city>
        <state>Västernorrland</state>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Styrke, MD</last_name>
      <phone>0046-70-2992048</phone>
      <email>johan.styrke@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingborgs Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magnus Wagenius, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Umea University Hospital</name>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Fridriksson, MD</last_name>
      <email>jon.fridriksson@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ängelholm hospital</name>
      <address>
        <city>Ängelholm</city>
        <zip>26281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magbus Wagenius, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Isen K, Küpeli B, Sinik Z, Sözen S, Bozkirli I. Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole. Int Urol Nephrol. 1999;31(4):491-5.</citation>
    <PMID>10668944</PMID>
  </reference>
  <reference>
    <citation>Lundström KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, Bill-Axelson A. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014 Oct;192(4):1116-22. doi: 10.1016/j.juro.2014.04.098. Epub 2014 May 9.</citation>
    <PMID>24813343</PMID>
  </reference>
  <reference>
    <citation>Wagenlehner FM, Bartoletti R, Cek M, Grabe M, Kahlmeter G, Pickard R, Bjerklund-Johansen TE. Antibiotic stewardship: a call for action by the urologic community. Eur Urol. 2013 Sep;64(3):358-60. doi: 10.1016/j.eururo.2013.05.044. Epub 2013 May 29.</citation>
    <PMID>23746854</PMID>
  </reference>
  <reference>
    <citation>Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011 Jun 9;11:450. doi: 10.1186/1471-2458-11-450.</citation>
    <PMID>21658213</PMID>
  </reference>
  <reference>
    <citation>Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659-67. doi: 10.1007/s10654-009-9350-y. Epub 2009 Jun 6.</citation>
    <PMID>19504049</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Biopsy</keyword>
  <keyword>Infection</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Antibiotic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

